ERDRP-0519, an orally bioavailable small-molecule Measles virus (MeV) polymerase inhibitor, prevents measles disease in squirrel monkeys (Saimiri sciureus). ERDRP-0519 inhibits morbilliviruses with nanomolar potency.[1][2][3].
ERDRP-0519 exhibits potency against a panel of Measles virus (MeV) isolates with EC50s of 0.07- 0.3 µM[1]. ERDRP-0519 exhibits potency against MeV and related pathogens of the Morbillivirus genus, such as canine distemper virus (CDV)[3].
A single-dose pharmacokinetic (PK) study is performed in squirrel monkeys by oral (intragastric) delivery of ERDRP-0519 (50 mg/kg) and blood sampling at seven predefined time points after dosing. Serum concentrations peak ~2 h post-administration (Cmax=3.27 µM)[3].
[1]. Wittwer K, et al. Small-molecule polymerase inhibitor protects non-human primates from measles and reduces shedding. Nat Commun. 2021 Sep 2;12(1):5233.